French drugmaker Sanofi (Euronext: SAN) says it expects to take a post-tax hit of about 100 million euros ($118 million) after new safety data showed its dengue vaccine Dengvaxia could be harmful to those not previously infected with the disease.
As a result, the company says it will request authorities slim down its label to ensure that vaccination is not recommended for those who have not been infected in the past.
Based on up to six years of clinical data, Sanofi found that patients of this type could suffer more cases of severe disease upon a subsequent dengue infection.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze